New updates have been reported about HistoSonics (PC:HISTO)
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
HistoSonics, a leader in non-invasive tumor treatment technology, has been awarded the Charles A. Sanders Award for Entrepreneurial Excellence by Hatteras Venture Partners. This recognition highlights HistoSonics’ groundbreaking work in developing and commercializing histotripsy, a novel ultrasound-based therapy that mechanically destroys tumors without invasive procedures. The award underscores the company’s significant impact on liver cancer treatment and its successful commercial launch, which has been described as one of the most successful in medical device history.
In a significant strategic development, HistoSonics announced in August 2025 that it would be acquired by a consortium of wealthy families and sovereign wealth funds in a deal valued at $2.25 billion. This acquisition marks a pivotal moment for the company, providing it with substantial resources to expand its innovative Edison System, which is currently focused on liver treatments, into other areas such as kidney, pancreas, and prostate applications. CEO Mike Blue expressed gratitude for the recognition and support from Hatteras Venture Partners, which has been instrumental in the company’s journey since its inception in 2009. As HistoSonics continues to push the boundaries of medical innovation, this award and acquisition position the company for further growth and impact in the healthcare sector.